Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension

被引:23
作者
Vyzantiadis, Timoleon [1 ]
Karagiannis, Asterios [1 ]
Douma, Stella [1 ]
Harsoulis, Phaedon [1 ]
Vyzantiadis, Athanasios [1 ]
Zamboulis, Chrysanthos [1 ]
机构
[1] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece
关键词
vascular endothelial growth factor; nitric oxide; arterial hypertension;
D O I
10.1080/10641960600945348
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vascular endothelial growth factor (VEGF) is a specific mitogen for endothelial cells and an inducer of the angiogenic procedure. Endothelial nitric oxide (NO) is a potent vasodilator. Because both are implicated in vascular function, it is possible that they would be significantly affected in arterial hypertension. The aim of the study was the investigation of the levels of the two substances in blood serum and their potential relation in patients with untreated essential arterial hypertension compared to healthy individuals. VEGF levels were found 129.1 +/- 135.9 pg/mL in a group of 28 untreated hypertensive patients vs. 209.0 +/- 133.3 pg/mL in a group of 28 healthy individuals (p = 0.008). Nitrites and nitrates levels (as an indirect index of calculating NO levels) were also lower in hypertensive patients than in healthy individuals (19.8 +/- 9.7 mu mol/L vs. 29.6 +/- 15.9 mu mol/L, p = 0.014). A positive correlation between NOx (nitrites and nitrates levels) and VEGF was found in healthy individuals (r = 0.55, p = 0.003), but there was no correlation in hypertensive patients. The significant decrease of serum VEGF and NO in arterial hypertension and the existence of a correlation between the two substances in healthy subjects that did not exist in the hypertensive patients are findings that need evaluation.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 37 条
[1]  
Arroyo MVA, 1998, KIDNEY INT, V54, pS7
[2]   Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology [J].
Banks, RE ;
Forbes, MA ;
Kinsey, SE ;
Stanley, A ;
Ingham, E ;
Walters, C ;
Selby, PJ .
BRITISH JOURNAL OF CANCER, 1998, 77 (06) :956-964
[3]   Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension [J].
Belgore, FM ;
Blann, AD ;
Li-Saw-Hee, FL ;
Beevers, DG ;
Lip, GYH .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (06) :805-+
[4]   Secondary endothelial dysfunction: Hypertension and heart failure [J].
Boulanger, CM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (01) :39-49
[5]   Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells [J].
Bouloumié, A ;
Schini-Kerth, VB ;
Busse, R .
CARDIOVASCULAR RESEARCH, 1999, 41 (03) :773-780
[6]  
COLLER BS, 1991, HEART CARDIOVASCULAR, V1, P219
[7]   AMINO-ACID AND CDNA SEQUENCES OF A VASCULAR ENDOTHELIAL-CELL MITOGEN THAT IS HOMOLOGOUS TO PLATELET-DERIVED GROWTH-FACTOR [J].
CONN, G ;
BAYNE, ML ;
SODERMAN, DD ;
KWOK, PW ;
SULLIVAN, KA ;
PALISI, TM ;
HOPE, DA ;
THOMAS, KA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) :2628-2632
[8]   PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].
FERRARA, N ;
HENZEL, WJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858
[9]   MOLECULAR AND BIOLOGICAL PROPERTIES OF THE VASCULAR ENDOTHELIAL GROWTH-FACTOR FAMILY OF PROTEINS [J].
FERRARA, N ;
HOUCK, K ;
JAKEMAN, L ;
LEUNG, DW .
ENDOCRINE REVIEWS, 1992, 13 (01) :18-32
[10]   Basal nitric oxide synthesis in essential hypertension [J].
Forte, P ;
Copland, M ;
Smith, LM ;
Milne, E ;
Sutherland, J ;
Benjamin, N .
LANCET, 1997, 349 (9055) :837-842